Intarcia Therapeutics

company

About

Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.

  • 251 - 500

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$10M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical Device,Personal Health
Founded date
Jan 1, 1997
Number Of Employee
251 - 500
Operating Status
Active

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides.

Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity.

David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$10M
Intarcia Therapeutics has raised a total of $10M in funding over 2 rounds. Their latest funding was raised on Apr 26, 2005 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 26, 2005 Debt Financing $10M 1 Horizon Technology Finance Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Intarcia Therapeutics is funded by 1 investors. Horizon Technology Finance are the most recent investors.
Investor Name Lead Investor Funding Round
Horizon Technology Finance Yes Debt Financing